SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Martek Biosciences Corp – ‘8-K’ for 5/20/02

On:  Monday, 5/20/02, at 5:17pm ET   ·   For:  5/20/02   ·   Accession #:  950133-2-2070   ·   File #:  0-22354

Previous ‘8-K’:  ‘8-K’ on 5/3/02 for 4/25/02   ·   Next:  ‘8-K/A’ on / for 7/5/02   ·   Latest:  ‘8-K’ on 2/25/11 for 2/18/11

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/20/02  Martek Biosciences Corp           8-K:5       5/20/02    1:17K                                    Bowne - DC/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     18K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  e8-k  

 



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2002

Martek Biosciences Corporation
(Exact name of registrant as specified in its
charter)

         
Delaware   000-22354   52-1399362

(State or other jurisdiction of   (Commission File   (I.R.S. Employer
incorporation or organization)   Number)   Identification No.)
         
6480 Dobbin Road    Columbia, Maryland     21045  

(Address of principal executive offices)     (Zip Code)  

Registrant’s telephone number, including area code: (410) 740-0081


(Former name or former address, if changed since last report)



 



 

MARTEK BIOSCIENCES CORPORATION

     
Item 5.   Other Events

        On May 20, 2002, a Registration Statement on Form S-3 (SEC File No. 333-87934) relating to the resale of up to 1,776,306 shares of common stock of Martek Biosciences Corporation (“Martek” or the “Registrant”) was declared effective by the Securities and Exchange Commission (“SEC”). Under the Registration Statement, former stockholders and creditors of OmegaTech, Inc., which was acquired by Martek on April 25, 2002, may offer for sale initially up to 1,265,213 shares of Martek common stock from time to time on the Nasdaq national market or through block sales or other methods at their discretion. The remainder of the shares may be offered for sale following the expiration of various lock-up or escrow agreements.

        In connection with the effectiveness of the Registration Statement, certain individuals listed in the table below each entered into a Selling Plan under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, with Adams, Harkness & Hill, Inc. (“AH&H”). Under the Selling Plans, AH&H will undertake to sell for each of these individuals the number of shares listed in the table below. AH&H will have the discretion to sell the number of shares covered by the Selling Plans at or above a set minimum price for a period up to June 7, 2002 and shall sell the remaining shares at the best price that secures timely liquidity after June 7, 2002.

                     

Name   Martek Title   Number of Shares
                Covered by Selling
        Plan

Mark Braman
  Executive Vice President     24,937  

James Flatt
  Senior Vice President –     7,866  
 
  Research and Development        

Robert Di Scipio
  Vice President, Associate     15,500  
 
  General Counsel and        
 
  Assistant Secretary        

Michael Klacik
  Director of     8,440  
 
  Business Development        

William Barclay
  Director of Discovery     6,497  

     
Item 7.   Financial Statements, Pro Forma Financial Information and Exhibits

        None.

-2-



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

             
        MARTEK BIOSCIENCES CORPORATION
             
Date: May 20, 2002   By:   /s/ George P. Barker
           
            George P. Barker
            Senior Vice President, General
            Counsel and Secretary

-3-


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
6/7/02
Filed on / For Period End:5/20/02S-3/A
4/25/028-K,  8-K/A
 List all Filings 
Top
Filing Submission 0000950133-02-002070   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 4:46:06.2am ET